Moderna, Inc.

Moderna filed an officer departure 8-K in early July 2026, triggering our red-flag detection system. While a single departure doesn't constitute material distress, the timing and context matter—particularly given the biotech sector's sensitivity to leadership changes and pipeline execution risk. Our 90-day window captured this event, but the full $49 Report extends the analysis back 12 months, cross-references financing history, quantifies dilution risk from equity issuances, and surfaces AI-driven signals on pipeline viability and cash burn trajectory. The full $49 Report adds a complete officer departure timeline, dilution risk score, and 12-month financing context that separates signal from noise.